Want to join the conversation?
Evercore ISI analyst David Togut follows up asking how much of DST acquisition revenue $BR has built into the FY17 revenue guidance. $BR says that about $440MM of fee and a little over $700MM of distribution revenue is built into FY17 guidance.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.
Well this is big! I don’t know if it’s someone’s monopoly or genuine excitement, but either way, $CSX is up 23% after market closed. I heard some activist investor is going to blow big money into CSX Corp. Anyone mind explaining?